ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

ANNX Annexon Inc

5.115
0.045 (0.89%)
Última actualización: 11:05:23
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Annexon Inc ANNX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.045 0.89% 5.115 11:05:23
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.04 4.98 5.21 5.07
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
12/6/202411:28EDGAR2Form 8-K - Current report
07/6/202420:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202420:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202420:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202420:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202415:42EDGAR2Form 8-K - Current report
06/6/202420:57EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/6/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202416:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/6/202406:05EDGAR2Form 8-K - Current report
13/5/202415:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202415:05EDGAR2Form 8-K - Current report
16/4/202408:00GLOBETurnstone Biologics Appoints William Waddill to its Board of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202414:15EDGAR2Form 144 - Report of proposed sale of securities
20/2/202414:12EDGAR2Form 144 - Report of proposed sale of securities
14/2/202419:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202418:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202418:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202418:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202417:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202415:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202414:45EDGAR2Form 144 - Report of proposed sale of securities
12/2/202414:41EDGAR2Form 144 - Report of proposed sale of securities
12/2/202414:39EDGAR2Form 144 - Report of proposed sale of securities
23/1/202416:00EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
23/1/202415:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:09EDGAR2Form 8-K - Current report
07/1/202419:00GLOBEAnnexon Outlines 2024 Priorities with Late-Stage Clinical..
29/12/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:50EDGAR2Form 144 - Report of proposed sale of securities
27/12/202305:30GLOBEAnnexon Biosciences to Present at the 42nd Annual J.P...
22/12/202316:28EDGAR2Form 8-K/A - Current report: [Amend]
21/12/202315:09EDGAR2Form 8-K - Current report
21/12/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/12/202316:27GLOBEAnnexon Announces Pricing of $125.0 Million Underwritten..
20/12/202316:24EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
20/12/202316:17EDGAR2Form 8-K - Current report
20/12/202316:10GLOBEAnnexon Outlines Global Registrational Program for ANX007 in..
20/12/202316:08GLOBEAnnexon Reports Phase 1 Results for ANX1502, its Oral Small..
18/12/202315:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
22/11/202315:01GLOBEAnnexon Biosciences to Participate in the 6th Annual..
13/11/202315:10EDGAR2Form 8-K - Current report
13/11/202305:30GLOBEAnnexon Reports Significant Progress with its Priority..
09/11/202305:30GLOBEAnnexon Biosciences to Participate in 2023 Jefferies London..
24/10/202315:30EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock